TrovaGene (NASDAQ:TROV) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS

TrovaGene (NASDAQ:TROV) posted its quarterly earnings data on Thursday. The medical research company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.27), Bloomberg Earnings reports. The company had revenue of $0.14 million for the quarter. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%.

NASDAQ:TROV traded down $0.04 during trading hours on Friday, reaching $1.63. The company’s stock had a trading volume of 62,378 shares, compared to its average volume of 64,116. The company has a market capitalization of $9.25 million, a price-to-earnings ratio of -0.20 and a beta of 0.74. The firm’s 50-day moving average price is $2.14. TrovaGene has a 1 year low of $1.60 and a 1 year high of $9.65. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.76 and a quick ratio of 3.76.

TROV has been the topic of several research reports. Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of TrovaGene in a research report on Friday. ValuEngine upgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Zacks Investment Research cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Finally, Noble Financial set a $23.00 price objective on shares of TrovaGene and gave the company a “buy” rating in a research report on Friday, May 24th.

About TrovaGene

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Featured Story: Why do earnings reports matter?

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.